Targeting RAGE in tumor and TME to oppose inflammation and drug resistance in obesity associated ER+ breast cancer

靶向肿瘤和 TME 中的 RAGE，对抗肥胖相关 ER 乳腺癌的炎症和耐药性

• 批准号: 10734834
• 负责人: Barry Ian Hudson
• 金额: $ 51.65万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-07 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10734834
• 关键词: Adipocytes; American; Automobile Driving; Binding; Biological Assay; Breast Cancer Cell; Breast Cancer Patient; Breast Cancer Risk Factor; Breast Cancer therapy; Breast cancer metastasis; CCL2 gene; Cancer Cell Growth; Cancer Patient; Cells; Cessation of life; Cytokine Gene; Data; Disease; Drug resistance; ESR1 gene; Endocrine; Endothelial Cells; Environment; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen receptor positive; Estrogens; Estrone; Fatty acid glycerol esters; Fulvestrant; Future; Gene Activation; Gene Expression; Genes; Goals; Growth; Human; IL6 gene; Immune; Immune Evasion; Immunologic Stimulation; Impairment; In Vitro; Infiltration; Inflammation; Inflammatory; Life Style; Ligands; MCF7 cell; Malignant Neoplasms; Mediating; Mediator; Modeling; Mus; Mutation; Myeloid-derived suppressor cells; Neoplasm Metastasis; Obese Mice; Obesity; Oncogenic; Organoids; Outcome; Pharmacotherapy; Postmenopause; Premenopause; Preventable cancer cause; Repression; Resistance; Response Elements; Risk; S100A8 gene; Signal Transduction; TLR4 gene; Testing; Therapeutic; Thinness; Tumor Immunity; Work; acquired drug resistance; cancer stem cell; cancer subtypes; cell type; chemokine; clinical investigation; comorbidity; cytokine; diet-induced obesity; effective therapy; gene induction; hormone therapy; immunoregulation; in vivo; inhibitor; inhibitor therapy; malignant breast neoplasm; mammary; mortality; mouse model; mutant; neoplastic cell; novel strategies; obese patients; obesity treatment; patient derived xenograft model; preclinical study; programs; receptor for advanced glycation endproducts; recruit; response; single-cell RNA sequencing; stem cell expansion; synergism; therapy resistant; transcription factor; transcriptome; transcriptomics; treatment response; tumor; tumor microenvironment; tumor progression; weight loss intervention

PROJECT SUMMARY/ABSTRACT Obesity is associated with increased postmenopausal estrogen receptor-positive (ER+) breast cancer (BC) risk and a 2-4 fold increase in mortality from all BC subtypes. Mechanisms of increased resistance to therapy and ensuing fatal BC metastasis in obesity remain unclear. Here, we study how the inflammatory state of obesity drives ER+ BC. We study how postmenopausal estrogen, estrone (E1), which is 3-fold higher in obesity, co- operates with NFκB and the Receptor for Advanced Glycation End-products (RAGE) to upregulate metastasis. Our data indicate that BC cell:adipocyte contact activates NFκB and E1:ERα to induce pro-inflammatory cytokine genes in both cell types, stimulating greater cancer stem cell expansion, and rapid ER+ BC growth and metastasis. Preliminary data show NFκB and E1:ER co-stimulate genes encoding RAGE-ligands (S100A8/A9). RAGE is a major NFκB activator in other cell types (including immune and endothelial cells), but little is known of RAGE/NFκB signaling in BC. We showed that RAGE acts in both tumor cells and the host microenvironment (stroma and fat) to upregulate cytokines that recruit myeloid-derived suppressor cells (MDSC) to promote metastasis. In obese mice, E1 increases BC growth, in part by stimulating immune evasion. New data show antiestrogen-resistant ER+BC lines, including those bearing ESR1 mutations, show increased NFκB activity and RAGE levels. Moreover, the investigational RAGE inhibitor, TTP488, cooperates with the ER-blocker, fulvestrant, to arrest antiestrogen-resistant ER+ BC cell growth in multiple resistant lines. Here, we test if E1-bound ER, NFκB, and RAGE interact in ER+ BC, adipocytes and immune cells to drive gene programs of endocrine therapy resistance and if RAGE inhibitors reverse this. We hypothesize that E1:ER and NFκB cooperate to induce RAGE, and RAGE activates NFκB in ER+ BC tumor cells and peritumoral fat to drive pro-inflammatory, pro-metastatic gene expression programs of tumor progression and acquired drug resistance. Aim 1 will identify tumor cell-intrinsic feed-forward mechanisms mediating RAGE/ NFκB activation in an E1-rich breast cancer environment, testing if E1 and NFκB induce RAGE to activate Rac1, and TLR4 driving feed-forward oncogenic NFκB activation in ER+ BC. Aim 2 will test if RAGE mediates pro-oncogenic, pro-inflammatory target gene activation by E1/ER and NFκB in breast cancer cells. We will identify E1/ER and NFκB cistromes and transcriptomes and test if these require RAGE. The relevance of RAGE-dependent ER/κB co-target genes activation in obesity will be validated by comparing ScRNAseq in human ER+ breast cancers from obese and lean donors. Aim 3 will identify tumor cell-extrinsic mechanisms whereby peritumoral fat in obese hosts promotes acquired antiestrogen resistance and immune evasion in ER+ cancers. Aim 4 will test if RAGE inhibitors restore endocrine therapy responses in organoid and PDX models derived from ER+ breast cancers. This work could identify new approaches to treating acquired endocrine resistance in metastatic ER+BC, particularly in obese patients.

项目总结/文摘